Pharmaceutical Distribution at a Crossroads: Growth, Complexity, and the Evolving Cold Chain 

Published August 2026 | Author: Leading Minds Network 

The following is a summary of a presentation delivered by Chris Anderson, Director of Quality Management at Cardinal Health, during a 2026 Leading Minds Network seminar. Anderson oversees quality systems, temperature management, data science, and specialty quality operations within Cardinal Health’s pharmaceutical distribution business and serves on the United States Pharmacopeia (USP) Packaging and Distribution Expert Committee.

Key Takeaways 

• Cold-chain pharmaceuticals are now driving industry growth. All five of the fastest-growing drugs in the U.S. are refrigerated products, highlighting the increasing importance of temperature-controlled distribution across the pharmaceutical supply chain. 
• Wholesale distributors remain the backbone of U.S. pharmaceutical distribution. Approximately 96% of pharmaceutical products move through wholesale distributors, making their role critical in maintaining product quality, availability, and patient access. 
• New storage classifications are creating operational challenges. The growing number of products labeled for storage between 2 °C and 25 °C offers greater flexibility but introduces confusion for distributors, healthcare providers, and patients regarding proper handling and transportation.
• USP standards are evolving to reflect modern distribution realities. Upcoming updates to USP chapters covering controlled room temperature definitions, lane qualification, and packaging validation aim to improve global harmonization and provide more practical guidance for supply chain stakeholders. 
• Mail-order and home-delivery models require greater scrutiny. As prescription fulfillment increasingly shifts toward direct-to-patient delivery, ensuring consistent temperature control during the final mile remains one of the industry's most important, and unresolved, challenges. 
  
  

A Supply Chain Under Pressure 

If there was one message that came through clearly in Anderson’s presentation, it was that pharmaceutical distribution is growing faster, and becoming more complicated, than ever before.

The U.S. pharmaceutical market reached approximately $923 billion in sales last year, growing 12% year-over-year and nearly 70% since 2000. Much of that growth is driven by specialty therapies, biologics, and temperature-sensitive products. Traditional pharmaceuticals grew roughly 10%, while specialty products expanded by approximately 15%.

Perhaps most notably, all the five fastest-growing drugs by sales are now refrigerated products. Three are GLP-1 therapies used for obesity and diabetes management, while the remaining products are specialty medicines.

This reflects a dramatic shift in the industry toward therapies that require strict temperature control throughout their journey from manufacturer to patient.

For distributors, this trend presents both opportunity and challenge. Cold-chain pharmaceuticals are growing at roughly twice the rate of traditional controlled room temperature products, creating increasing demands on storage infrastructure, packaging systems, transportation networks, and compliance programs.

The Cold Chain Becomes the Mainstream 

Years ago, refrigerated pharmaceuticals represented a specialized niche. Today, they sit at the center of pharmaceutical growth.

Anderson highlighted how healthcare providers, distributors, and manufacturers must adapt to a market increasingly dominated by products requiring storage between 2 °C and 8 °C. Distribution centers are adding refrigerated capacity, investing in freezers, expanding gel-pack production capabilities, and rethinking warehouse layouts to accommodate changing product portfolios.

Yet improvements that benefit patients can create operational complexities elsewhere in the supply chain.

For example, certain vaccines and biologics that previously required frozen storage are now approved for refrigerated conditions, simplifying handling for healthcare providers. However, distributors may then need to manage multiple temperature profiles for the same customer, increasing packaging requirements and transportation complexity.

"It is often easier for the patient and provider, but harder for the distributor," was a recurring theme throughout the discussion.

The Rise of New Storage Categories 

Another major issue Anderson addressed was the growing use of pharmaceutical labels specifying storage conditions between 2 °C and 25 °C.

Historically, many products were categorized as either refrigerated (2–8 °C) or controlled room temperature products. The new hybrid category offers greater flexibility but creates confusion throughout the supply chain.

Distributors must develop packaging and transportation systems capable of maintaining these broader ranges. Customers, meanwhile, often struggle to understand whether products should remain refrigerated or can safely be stored at warmer temperatures.

The challenge is partially psychological. A package arriving at 20 °C may feel warm compared to a traditional refrigerated product arriving at 5 °C, even though both are fully compliant with their storage requirements.

As manufacturers continue to expand temperature allowances based on improved stability data, education throughout the healthcare ecosystem will become increasingly important.

Why Distribution Needs a Bigger Voice 

One of Anderson’s strongest messages focused on representation.

He asked attendees a simple but revealing question: What percentage of pharmaceutical products move directly from manufacturers to healthcare providers, and what percentage move through wholesale distributors?

The answer surprised many.

According to Anderson, approximately 96% of pharmaceutical volume in the U.S. passes through wholesale distributors, while only 4% moves through direct channels.

Yet historically, many conversations around packaging standards, temperature management, and regulatory guidance have been driven primarily by manufacturers.

When Anderson first became involved with USP committees, he was struck by how few distribution professionals participated in developing standards that would significantly impact the distribution sector. Since then, one of his goals has been to bring greater operational expertise into industry working groups and expert committees.

His argument is straightforward: most pharmaceutical products ultimately travel through distributor networks, making practical distribution knowledge essential when creating industry standards. This perspective echoes a similar message he previously shared regarding the importance of incorporating distribution realities into pharmaceutical cold-chain policy discussions.

Inventory Compression and Capacity Challenges 

Growth has also transformed inventory management practices. Wholesale distributors once maintained approximately 30 days of inventory. Today that figure has dropped closer to 22 days.

Part of the reduction is financial, improving cash flow and working capital efficiency. But another factor is simply the increasing number of products entering the market. Facilities that were designed to support years of future growth are reaching capacity much sooner than anticipated.

The industry is becoming more efficient, but it is also operating with progressively smaller margins for error.

Refrigerated storage presents challenges. As more products require controlled temperatures, distributors must continuously expand cold storage infrastructure, add freezer space, and increase thermal packaging capabilities.

USP and the Future of Pharmaceutical Distribution Standards  

A significant portion of the presentation focused on the work being performed by USP's Packaging and Distribution Expert Committee.

Anderson currently leads USP's Storage and Transportation Subcommittee, which is focused on improving and harmonizing pharmaceutical distribution practices globally.

Several important developments are underway.

One proposed revision to USP Chapter <659> would expand the definition of Controlled Room Temperature from 20–25 °C to 15–25 °C. The change is intended to align U.S. standards with European and Japanese pharmacopeias and improve international harmonization. Similar updates and ongoing revisions to USP Chapters <659> and <1079> have been highlighted previously as part of the industry's effort to modernize temperature management practices.

Another major initiative is the publication of guidance on lane mapping, which helps organizations scientifically qualify transportation routes based on environmental conditions, transit times, and seasonal risks. Rather than monitoring every shipment individually, companies can establish confidence in specific transportation lanes through data-driven qualification studies.

Future work will focus on passive packaging qualification, with the goal of producing practical guidance that organizations of all sizes can understand and implement.

Importantly, Anderson emphasized that these standards are being written to be usable, not merely academic. The objective is to create guidance that helps companies make informed decisions without requiring excessive complexity or cost.

The Mail-Order Question 

One of the most thought-provoking discussions centered on mail-order pharmacy service.

Mail-order pharmaceutical sales continue to grow rapidly and now represent a substantial portion of the prescription market. While the model offers convenience and expands access, particularly in areas facing pharmacy closures, it also introduces new temperature-control concerns.

Last-mile delivery often leaves products exposed to uncontrolled conditions such as hot mailboxes, freezing porches, or prolonged outdoor storage.

Anderson expressed concern that the industry lacks sufficient visibility into what happens after a package reaches a residence. While many mail-order providers operate sophisticated temperature-controlled systems, standards and oversight remain inconsistent across the broader market.

His view was not that mail-order pharmacy is inherently flawed, but that it requires stronger qualification data, better monitoring practices, and greater transparency to ensure patient safety. Similar concerns about last-mile temperature excursions and inconsistent monitoring have been raised previously in discussions about growing mail-order pharmaceutical volumes.

Looking Forward

As pharmaceutical innovation accelerates, distribution is becoming an increasingly critical part of healthcare delivery.

The industry's future will depend on balancing growth, cost pressures, sustainability goals, regulatory expectations, and patient safety. For Anderson, the solution lies in collaboration—bringing manufacturers, distributors, regulators, packaging providers, and healthcare organizations together to solve common problems.

His closing message was simple but powerful: pharmaceutical distribution is no longer an invisible operational function. It is a strategic component of modern healthcare.

As more therapies become temperature-sensitive, biologic-based, and patient-specific, the ability to protect products throughout the supply chain will increasingly determine whether innovation ultimately reaches the people who need it most.

Frequently Asked Questions About Pharmaceutical Distribution

1. Why is cold-chain pharmaceutical distribution growing?

Cold-chain pharmaceutical distribution is growing because refrigerated medicines are now driving much of the industry’s growth. The article states that all five of the fastest-growing drugs in the U.S. are refrigerated products, including three GLP-1 therapies used for obesity and diabetes management and other specialty medicines. This shift is increasing demand for refrigerated storage, thermal packaging, transportation controls, and compliance programs across the pharmaceutical supply chain. 

2. How much of the U.S. pharmaceutical supply moves through wholesale distributors? 

According to Anderson’s presentation, approximately 96% of pharmaceutical volume in the U.S. passes through wholesale distributors, while only about 4% moves through direct channels. The article emphasizes that this makes wholesale distributors essential to maintaining product quality, product availability, and patient access. 

3. What does 2 °C to 25 °C storage mean for pharmaceutical products? 

The 2 °C to 25 °C storage range refers to a newer type of pharmaceutical labeling that allows certain products to be stored across a broader temperature range than traditional refrigerated products. The article explains that this can create more flexibility, but it also causes confusion because distributors, healthcare providers, and patients may be unsure whether a product should remain refrigerated or can safely be stored at warmer temperatures. A product arriving at 20 °C may feel warm compared with a traditional refrigerated shipment, even though it may still be fully compliant with its storage requirements.

4. How are USP standards changing for pharmaceutical storage and transportation?

USP standards are evolving to better reflect modern pharmaceutical distribution. The article notes that one proposed revision to USP Chapter <659> would expand the definition of Controlled Room Temperature from 20–25 °C to 15–25 °C in order to better align U.S. standards with European and Japanese pharmacopeias. The article also describes work on lane mapping guidance, which helps companies qualify transportation routes based on environmental conditions, transit times, and seasonal risks, as well as future guidance on passive packaging qualification.  

5. What are the temperature-control risks of mail-order pharmacies? 

Mail-order pharmacy can create temperature-control risks during the final stage of delivery. The article explains that last-mile delivery may expose medications to uncontrolled conditions such as hot mailboxes, freezing porches, or prolonged outdoor storage. Anderson’s concern is not that mail-order pharmacy is inherently flawed, but that it needs stronger qualification data, better monitoring practices, and greater transparency to help protect patient safety.